Observational Prospective Study on Patients Treated With Norditropin®

Condition(s) targeted: Growth Hormone Disorder; Growth Hormone Deficiency in Children; Adult Growth Hormone Deficiency; Genetic Disorder; Turner Syndrome; Foetal Growth Problem; Small for Gestational Age; Chronic Kidney Disease; Chronic Renal Insufficiency; Noonan Syndrome

Intervention: somatropin (Drug); somatropin (Drug)

Phase: N/A

Status: Enrolling by invitation

Sponsored by: Novo Nordisk A/S

Official(s) and/or principal investigator(s):
Global Clinical Registry (GCR, 1452), Study Director, Affiliation: Novo Nordisk A/S

This observational study is conducted globally. The aim of the study is to investigate the effectiveness and safety of real-life treatment with Norditropin®. The study population will consist of children and adults who are on treatment with Norditropin® in accordance with normal clinical practice.

Official title: NordiNet® International Outcome Study-Observational Prospective Study on Patients Treated With Norditropin®

Study design: Observational Model: Cohort, Time Perspective: Prospective

Primary outcome:

Effect of Norditropin® treatment on height gain (change in height) in children

Effect of Norditropin® treatment on body weight and body composition in adults

Secondary outcome:

Effect of Norditropin® treatment body weight, blood biochemistry, bone age, the endocrine system and pubertal development in children

Effect of Norditropin® treatment on quality of life, blood biochemistry and the endocrine system in adults

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Judged by the physician as per the Norditropin® label

Exclusion Criteria:

- Judged by the physician as per the Norditropin® label

Prov. de Buenos Aires B1636DSU, Argentina

Brussels 1070, Belgium

Prague 16000, Czech Republic

Copenhagen S 2300, Denmark

Espoo FI-02600, Finland

Belgrade 11 070, Former Serbia and Montenegro

Paris La défense cedex 92932, France

Mainz 55127, Germany

Budapest 1025, Hungary

Dublin 2, Ireland

Kfar Saba 44425, Israel

Rome 00144, Italy

Vilnius 01112, Lithuania

Luxembourg, Luxembourg

Alphen a/d Rijn, Netherlands

Rud 1309, Norway

Moscow 119330, Russian Federation

Riyadh 3542, Saudi Arabia

Ljubljana SI-1000, Slovenia

Madrid 28033, Spain

Malmö 202 15, Sweden

Zurich CH-8050, Switzerland

Crawley RH11 9RT, United Kingdom

Clinical Trials at Novo Nordisk

Starting date: April 2006
Last updated: June 1, 2015